What is the official ID of this bill?
The official print number for this legislation is HR 1199.
Ensuring Medicare Access to Innovative Diagnostic Radiopharmaceuticals
This Act ensures that Medicare beneficiaries maintain access to modern diagnostic radiopharmaceuticals used for disease detection. The change introduces a separate payment mechanism for these expensive drugs in hospital outpatient settings, instead of bundling them into the overall procedure cost. This encourages hospitals to utilize innovative, yet costly, diagnostic methods, directly improving the quality of healthcare for seniors.
Key points
Separate Payment for Costly Drugs: Medicare will pay separately for certain innovative diagnostic radiopharmaceuticals if their cost exceeds $500 (the threshold for 2024).
Improved Diagnostic Access: Hospitals will be more likely to offer the latest diagnostic methods, as their cost will no longer be absorbed by the general outpatient procedure budget.
No Impact on Patient Copayments: The change in payment method for hospitals will not affect the amount of copayments borne by Medicare patients.
Implementation Starting January 1, 2024: The new payment rules will take effect at the beginning of 2024.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.